# Nuclear Medicine Cheatsheet

## Table of Contents
- [Basic Principles](#basic-principles)
- [Types of Radiation](#types-of-radiation)
- [Imaging Techniques](#imaging-techniques)
- [Radiopharmaceuticals](#radiopharmaceuticals)
- [Clinical Applications](#clinical-applications)
- [Therapeutic Applications](#therapeutic-applications)
- [Dosimetry & Safety](#dosimetry--safety)
- [Instrumentation & Quality Control](#instrumentation--quality-control)
- [Recent Advances & Future Trends](#recent-advances--future-trends)

## Basic Principles
### Definition:
#### ğŸ“Œ **Nuclear Medicine:** 
- A branch of medicine and medical imaging that uses radioactive substances (radiopharmaceuticals) for diagnosis, treatment, and research.

### ğŸ“Œ **Radiopharmaceuticals:**
- **What are they?** 
  - **Radiopharmaceutical** = ğŸ’Š (Pharmaceutical) + â˜¢ï¸ (Radioactive Isotope)
- **Purpose:** 
  - Radiopharmaceuticals are taken up by specific organs, tissues, or cells, allowing them to be visualized during imaging or to deliver therapeutic radiation to targeted sites.

[Back to top](#nuclear-medicine-cheatsheet)

## Types of Radiation


### ğŸ”µ Alpha Radiation (Î±):

**General Characteristics:**

- ğŸ“Œ Composed of 2 protons and 2 neutrons.
- ğŸ§² Positively charged.
- ğŸš§ Short range in tissues and can be stopped by a sheet of paper or human skin.

**Common Alpha Emitters in Nuclear Medicine:**

- **Radium-223 (Ra-223)**
  - ğŸ“ **Usage:** Treatment of bone metastases in patients with castration-resistant prostate cancer.
  - âš› **Decay Mechanism:** Undergoes a series of alpha decays to become stable lead.
  - ğŸ¯ **Why Used:** The emitted alpha particles are high linear energy transfer (LET) particles, meaning they can cause a significant amount of local damage, making them useful for targeted therapy of metastatic lesions in bones.

### ğŸ”´ Beta Radiation (Î²):

**General Characteristics:**

- â– Beta Minus (Î²-) involves emission of electrons.
- â• Beta Plus (Î²+) involves emission of positrons.
- ğŸš€ Longer range than alpha particles but less than gamma rays.

**Common Beta Emitters in Nuclear Medicine:**

- **Yttrium-90 (Y-90)**
  - ğŸ“ **Usage:** Used in radioimmunotherapy and for liver cancer treatments using microspheres.
  - âš› **Decay Mechanism:** Î²- emitter that decays to stable Zirconium-90.
  - ğŸ¯ **Why Used:** Due to its relatively long half-life and pure beta emission, it delivers a high dose of radiation to targeted tissues.
  
- **Fluorine-18 (F-18)**
  - ğŸ“ **Usage:** Most commonly used in FDG-PET imaging for oncology.
  - âš› **Decay Mechanism:** Î²+ emitter that decays into Oxygen-18.
  - ğŸ¯ **Why Used:** Provides valuable metabolic information about tissues, with tumors typically showing increased FDG uptake due to higher metabolic activity.

### ğŸŒŒ Gamma Radiation (Î³):

**General Characteristics:**

- ğŸ’¡ Electromagnetic radiation (high-energy photons).
- ğŸ›¡ï¸ Deeply penetrating and requires shielding.

**Common Gamma Emitters in Nuclear Medicine:**

- **Technetium-99m (Tc-99m)**
  - ğŸ“ **Usage:** The most widely used radionuclide in diagnostic nuclear medicine. Used in a variety of scans such as bone scans, myocardial perfusion imaging, and renal scans.
  - âš› **Decay Mechanism:** Emits gamma radiation and decays to stable Technetium-99.
  - ğŸ¯ **Why Used:** Its 6-hour half-life is long enough to conduct the necessary diagnostic tests but short enough to minimize radiation dose to the patient. The emitted gamma energy (140 keV) is ideal for imaging with a gamma camera.
  
- **Iodine-131 (I-131)**
  - ğŸ“ **Usage:** Used for both diagnostic imaging and therapy, particularly for thyroid diseases.
  - âš› **Decay Mechanism:** Beta and gamma emitter.
  - ğŸ¯ **Why Used:** Accumulates in the thyroid gland, allowing imaging or targeted destruction of thyroid tissue.



| Radionuclide | Mean Positron Range (Rmean) (mm) | Maximum Positron Range (Rmax) (mm) |
|--------------|---------------------------------|-----------------------------------|
| 18F          | 0.44 - 0.57                     | 2.31 - 2.6                        |
| 64Cu         | 0.56                            | 2.9                               |
| 89Zr         | 0.87                            | 3.76                              |
| 15O          | 2.00 - 2.39                     | 8.01 - 10.3                       |
| 68Ga         | 2.70                            | 10.57                             |
| 124I         | 5.03 - 5.33                     | 16.80 - 18.6                      |


| Radionuclide      | Half-Life            |
|--------------------|----------------------|
| F-18 (Fluorine-18) | Approximately 109.7 minutes  |
| C-11 (Carbon-11)   | Approximately 20.3 minutes   |
| N-13 (Nitrogen-13) | Approximately 9.97 minutes   |
| O-15 (Oxygen-15)   | Approximately 2.03 minutes   |
| Rb-82 (Rubidium-82)| Approximately 1.27 minutes   |
| Ga-68 (Gallium-68) | Approximately 67.7 minutes   |
| I-124 (Iodine-124) | Approximately 4.18 days     |




[Back to top](#nuclear-medicine-cheatsheet)

## Imaging Techniques 


### 1. **Gamma Camera** ğŸ“¸

- **Principle**: A gamma camera captures gamma radiation from radiopharmaceuticals inside a patient's body, thereby providing a two-dimensional image.

- **Components**:
    - ğŸŒ€ **Collimator**: A lead shield with holes that only allows gamma rays traveling in specific directions to pass through, ensuring spatial resolution.
    - ğŸ› **Detector Crystal**: Typically made of sodium iodide or cesium iodide, this crystal emits flashes of light (scintillations) when hit by gamma rays.
    - ğŸ–¥ **Photomultiplier Tubes (PMTs)**: Positioned behind the crystal, these tubes detect the light from the crystal and convert it into an electrical signal.
    - ğŸ” **Computer System**: Takes the signals from the PMTs and constructs an image.

- **Operation**: After a patient is administered a radiopharmaceutical, the gamma camera captures emitted gamma rays, and a computer processes this data into an image.

- **Indications**:
    - Bone Scans: Detect bone metastases, fractures, infections, or inflammatory disorders.
    - Thyroid Scans: Evaluate thyroid function or detect tumors.
    - Renal Scans: Assess kidney function and drainage.
    - Cardiac Stress Tests: Determine areas of low blood flow.

- **Common Tracers**:
    - Technetium-99m (Tc-99m): Versatile and can be combined with various molecules to target specific organs.
    - Iodine-123 (I-123): Common for thyroid scans.

### 2. **SPECT (Single Photon Emission Computed Tomography)** ğŸ”„

- **How it Functions**: A SPECT scanner acquires multiple 2D images from various angles. A computer then uses these images to produce a 3D image, providing more detail about the body's internal structures.

- **Clinical Applications**: 
    - Brain: Analyze blood flow and detect abnormalities.
    - Heart: Detect coronary artery disease or myocardial infarctions.
    - Bones: Spot fractures, infections, or tumors.

- **Advantages over Planar Imaging**:
    - Provides 3D visualization, allowing for more accurate localization of lesions.
    - Offers better contrast resolution.

- **Common Tracers**:
    - Technetium-99m (Tc-99m): Modified for various target organs, including the brain, heart, and bones.

### 3. **PET (Positron Emission Tomography)** ğŸŒŒ

- **Basics of Positron Emission**: After a patient is injected with a positron-emitting radionuclide, the positron encounters an electron in the body. Their mutual annihilation produces two gamma rays, which travel in opposite directions and are captured by the PET camera.

- **Commonly Used Radionuclides**:
    - Fluorine-18 FDG (F-18 FDG): Sugar molecule analog that, when taken up by cells, indicates metabolic activity.

- **Clinical Applications**:
    - Oncology: Determine the stage of cancers, assess treatment efficacy, and detect recurrences.
    - Neurology: Diagnose conditions like Alzheimer's and evaluate epilepsy.
    - Cardiology: Evaluate perfusion and metabolism of the heart muscle.

- **Common Tracers**:
    - Fluorine-18 FDG: Used in tumor imaging, highlighting areas of increased glucose metabolism.
    - Rubidium-82: Cardiac PET imaging to assess myocardial blood flow.

### 4. **Hybrid Imaging** ğŸŒğŸ”—

- **Principle**: Merges anatomical (from CT or MRI) and functional (from SPECT or PET) images, allowing for enhanced diagnostic capability.

- **Techniques**:
    - **PET/CT**: Combines metabolic PET images with CT's anatomical detail, often used for cancer imaging.
    - **SPECT/CT**: Merges functional SPECT with anatomical CT, common in cardiac and orthopedic imaging.

- **Advantages**:
    - Pinpoint accuracy in lesion localization.
    - Better differentiation between benign and malignant lesions.
    - Streamlines patient management by reducing the need for multiple scans.

- **Common Tracers**:
    - Vary based on the specific modality and indication. For instance, a PET/CT for cancer diagnosis might use Fluorine-18 FDG, while a SPECT/CT for cardiac imaging could utilize Technetium-99m.


[Back to top](#nuclear-medicine-cheatsheet)

## Radiopharmaceuticals


### ğŸ› **Production of Radiopharmaceuticals**


#### ğŸŒ€ **Cyclotrons in Radiopharmacy**

**What are Cyclotrons? ğŸ¤”**
In radiopharmacy, cyclotrons are particle accelerators designed to produce high-energy protons or deuterons. These particles then bombard target materials to produce specific radionuclides.

**How Do Cyclotrons Work? ğŸ”**
Electric fields are set up in a cyclical pattern, causing the charged particles to spiral outwards, gaining energy as they go. The high-energy particles then strike a target material, causing nuclear reactions and the production of radionuclides.

**Applications in Radiopharmacy ğŸŒŸ:**
- Production of Fluorine-18 for PET imaging.
- Creation of other radionuclides for various diagnostic and therapeutic applications.

---

#### ğŸŒ‹ **Nuclear Reactors in Radiopharmacy**

**What are Nuclear Reactors? ğŸ¤”**
In the context of radiopharmacy, nuclear reactors are facilities that initiate, control, and sustain nuclear fission reactions, producing a slew of radionuclides in the process.

**How Do Nuclear Reactors Work? âš›ï¸**
A reactor uses controlled fission reactions of enriched Uranium-235 or other fissile materials. As these atoms split, they release energy and a variety of radionuclides.

**Key Role in Radiopharmacy ğŸ’¡:**
- Main source for producing Molybdenum-99.
- Enables production of several other radionuclides for medical use.

---

#### ğŸ› **Generators in Radiopharmacy**

**What are Generators? ğŸ¤”**
In radiopharmacy, a generator is a system that allows for the production of a short-lived daughter radionuclide from a longer-lived parent radionuclide. The daughter radionuclide is then used in medical applications, especially when it has a short half-life and cannot be easily transported from a central production facility to hospitals or imaging centers.

**How Do Generators Work? ğŸ”„**
The generator contains a parent radionuclide that decays into a daughter radionuclide. Once the daughter is formed, it can be extracted or "eluted" from the generator using an appropriate solvent (usually saline solution). This process is often referred to as "milking" the generator.

**The Mo-99/Tc-99m Generator: A Prime Example ğŸŒŸ**
The Molybdenum-99/Technetium-99m (Mo-99/Tc-99m) generator is the most well-known and widely used generator system in nuclear medicine.

- **Parent Radionuclide (Mo-99) â³:**
  - Half-life: 66 hours.
  - Decay Product: Technetium-99m (Tc-99m) through beta decay.
- **Daughter Radionuclide (Tc-99m) ğŸ“¸:**
  - Half-life: 6 hours.
  - Usage: Diagnostic imaging in nuclear medicine.

---

### ğŸŒ **Common and Exotic Radiopharmaceuticals in Medical Imaging**

#### **Technetium-99m Based Agents ğŸ§ª**

**Understanding Tc-99m: ğŸ¤”**
Tc-99m is a metastable gamma-emitting nuclear isomer. Due to its favorable radiation properties and short half-life, it's ideal for various imaging procedures.

**Applications ğŸŒŸ:**
- Bone scans using Tc-99m MDP.
- Myocardial perfusion imaging.
- Renal function assessments with Tc-99m MAG3.

#### **Fluorodeoxyglucose (F-18 FDG) ğŸ¬**

**Unpacking F-18 FDG: ğŸ¤”**
It's a glucose analog where a radioactive fluorine atom replaces hydroxyl. Tumors, being highly metabolic, consume more glucose, making F-18 FDG invaluable in oncology imaging.

**Applications ğŸŒŸ:**
- PET imaging to visualize metabolic activity in tumors.

---

### ğŸ”„ **Pharmacokinetics of Radiopharmaceuticals**

#### **Absorption in the Body ğŸ’‰**

**What is Absorption? ğŸ¤”**
It's the process by which radiopharmaceuticals move from the administration site into the bloodstream.

**Methods ğŸŒŸ:**
- Most common: Intravenous injection.
- Others: Inhalation or oral intake.

#### **Distribution in Tissues ğŸŒ**

**Understanding Distribution: ğŸ¤”**
After entering the bloodstream, the radiopharmaceutical is carried to various body tissues. The patterns depend on the specific agent and its chemical properties.

**Factors Influencing Distribution ğŸŒŸ:**
- Blood flow to organs.
- Binding to plasma proteins.
- Compound's lipophilicity.



[Back to top](#nuclear-medicine-cheatsheet)

## Clinical Applications

### **1ï¸âƒ£ Diagnostic and Staging Modalities in Oncology**
Nuclear medicine plays a pivotal role in the diagnosis, staging, and monitoring of various cancers. Through the use of different radiopharmaceuticals, the metabolic activity of tumors and their response to treatments can be studied in depth.

**A. FDG-PET/CT ğŸ“¸**

- **What is it?** PET using F-18 Fluorodeoxyglucose (FDG) combined with CT provides both metabolic and anatomical information. 
- **How it works?** Cancer cells often have increased glucose metabolism. FDG, a glucose analog, accumulates in these hypermetabolic cells, which can be detected with PET. 
- **Applications**:
  - **Initial Staging**: Helps determine the extent of disease at diagnosis.
  - **Re-staging**: Assesses the body post-treatment to check for residual or recurrent disease.
  - **Therapeutic Monitoring**: Evaluates how well a tumor is responding to therapy.
  - **Prognostication**: High uptake (SUV) can be correlated with a more aggressive tumor phenotype.

**B. Gallium-68 DOTA Peptides (Somatostatin Receptor Imaging) ğŸ“¸**

- **What is it?** Gallium-68 labeled peptides target somatostatin receptors present on the surface of neuroendocrine tumor cells.
- **Applications**:
  - **Tumor Detection**: Especially for neuroendocrine tumors of the pancreas, gut, and lungs.
  - **Follow-up**: Monitors disease progression or response to therapy.

**C. Prostate-Specific Membrane Antigen (PSMA) PET/CT ğŸ“¸**

- **What is it?** PSMA is a cell surface protein overexpressed in prostate cancer cells. Radiolabeled molecules targeting PSMA provide a means to image prostate cancer.
- **Applications**:
  - **Recurrence Detection**: Particularly in patients with rising PSA levels post-treatment.
  - **Staging**: Identifying lymph node metastases or distant spread.

### **2ï¸âƒ£ Therapeutic Monitoring and Follow-up**

**A. Therapy Response Assessment ğŸ”„**
- **Metabolic Response Criteria**: Using FDG-PET, therapy response can be gauged by the reduction in FDG uptake in tumors post-therapy.
- **Morphological Response**: Combined with CT or MRI, reduction in tumor size or changes in tumor characteristics can be analyzed.


### **What is Theranostics?**

Theranostics is a term that combines "therapy" and "diagnostics." It pertains to agents or procedures that combine both diagnostic imaging and therapeutic intervention, offering a two-in-one approach to patient management. By utilizing the same molecule or a similar molecular pathway for both diagnosis and treatment, personalized care becomes possible.

### **1ï¸âƒ£ Theranostic Pairings in Oncology**

**A. Prostate Cancer ğŸ§¬**
   
- **Diagnostic**: PSMA PET/CT for identifying prostate cancer lesions.
- **Therapeutic**: Lutetium-177 or Actinium-225 labeled PSMA ligands for radionuclide therapy. These agents emit radiation that can kill prostate cancer cells which express PSMA.

**B. Neuroendocrine Tumors ğŸ§¬**

- **Diagnostic**: Gallium-68 DOTA peptides (like DOTATATE) for imaging neuroendocrine tumors.
- **Therapeutic**: Lutetium-177 labeled DOTA peptides for peptide receptor radionuclide therapy (PRRT). The radiation emitted targets and destroys the tumor cells with somatostatin receptors.

### **2ï¸âƒ£ Advantages of Theranostics ğŸŒŸ**

- **Tailored Treatment**: Only patients with positive diagnostic scans are treated, ensuring that the therapy will target the disease effectively.
- **Monitoring**: Ability to image and assess the response to therapy using the same agent.
- **Fewer Side Effects**: As the therapy is targeted, there's potentially reduced harm to healthy tissues.

## ğŸŒ **Immuno-PET in Oncology**

### **What is Immuno-PET?**

Immuno-PET combines the specificity of antibodies with the sensitivity of PET imaging. It employs radiolabeled antibodies or fragments of antibodies to target and visualize immune processes in real-time.

### **1ï¸âƒ£ Applications**

**A. Tumor Microenvironment Imaging ğŸ–¼ï¸**

- **Purpose**: Visualizing tumor-infiltrating lymphocytes, macrophages, and other immune cells.
- **Relevance**: Provides insights into how 'hot' or 'cold' a tumor is, aiding in the decision for immunotherapy.

**B. Assessing Immunotherapy Responses ğŸ”„**

- **Purpose**: To determine if a patient is responding to immunotherapy.
- **Relevance**: Early response detection can guide whether to continue or switch treatment strategies.

**C. Predicting Immunotherapy Success ğŸ“Š**

- **Purpose**: Predict which patients are likely to benefit from immunotherapy.
- **Relevance**: Can prevent unnecessary treatments and their associated side effects.

### **2ï¸âƒ£ Challenges and Advancements ğŸš§**

- **Size of Antibodies**: Traditional antibodies are large and might not penetrate tumors effectively. Smaller fragments or engineered versions are being developed to overcome this.
- **Radiolabeling**: Choosing the right radionuclide to label the antibody without affecting its specificity or causing rapid degradation.
- **Clearance**: Ensuring that non-bound antibodies are cleared swiftly from the bloodstream to improve imaging contrast.

### ğŸ¦  **Major Cancers Diagnosed and Treated by Nuclear Medicine**

1. **ğŸ« Breast Cancer**
   - **ğŸ” Diagnostic**:
     - **ğŸ¬ FDG-PET**: This modality helps visualize the metabolic activity associated with primary tumors and metastatic lesions. Given that cancer cells often consume more glucose than normal cells, FDG accumulates in them, facilitating imaging.
     - **ğŸŒº FES-PET**: An imaging technique to visualize the estrogen receptor (ER) expression in breast cancer tumors, crucial for tailoring hormone-based therapies.
   - **ğŸ’‰ Therapeutic**:
     - **ğŸ“¿ PRRT (Peptide Receptor Radionuclide Therapy)**: Targets specific types of breast cancers expressing particular receptors.
     - **ğŸ›¡ï¸ Radiolabeled antibodies**: These are molecules tailored to bind to specific tumor markers, enabling targeted delivery of radiation.

2. **ğŸŒ° Prostate Cancer**
   - **ğŸ” Diagnostic**:
     - **ğŸ§¬ PSMA-PET**: A highly sensitive modality for detecting metastasis and recurrences in prostate cancer due to its ability to target the prostate-specific membrane antigen overexpressed in these cells.
   - **ğŸ’‰ Therapeutic**:
     - **âš›ï¸ Radium-223**: A targeted therapy for metastatic castration-resistant prostate cancer that has spread to bones but not other organs.
     - **ğŸ§¬ PSMA-targeted therapy**: Directly targets PSMA-expressing prostate cancer cells, delivering a lethal radiation dose.

3. **ğŸ« Lung Cancer**
   - **ğŸ” Diagnostic**:
     - **ğŸ¬ FDG-PET**: Especially beneficial in staging lung cancers and detecting recurrences by identifying regions of heightened metabolic activity.
   - **ğŸ’‰ Therapeutic**:
     - **ğŸ›¡ï¸ Radiolabeled antibodies**: Molecules designed to specifically target markers on lung cancer cells, providing a targeted radiation dose.

4. **ğŸ¦‹ Thyroid Cancer**
   - **ğŸ” Diagnostic**:
     - **ğŸŒ€ Radioiodine Scan**: Capitalizes on the affinity of differentiated thyroid cancers for iodine, helping in their detection.
   - **ğŸ’‰ Therapeutic**:
     - **ğŸŒ¡ï¸ I-131 therapy**: A mainstay for treating certain types of thyroid cancers post-operatively and for addressing metastatic differentiated thyroid cancers.

5. **ğŸ§  Neuroendocrine Tumors**
   - **ğŸ” Diagnostic**:
     - **ğŸŒŒ Gallium-68 DOTA Peptides PET**: These peptides specifically bind to somatostatin receptors expressed on neuroendocrine tumors, allowing for precise imaging.
   - **ğŸ’‰ Therapeutic**:
     - **ğŸ“¿ PRRT**: An effective treatment for somatostatin receptor-positive tumors, delivering targeted radiation.

6. **ğŸ§  Brain Cancers**
   - **ğŸ” Diagnostic**:
     - **ğŸ¬ FDG-PET**: Provides a general evaluation of brain tumors based on their metabolic activity.
     - **ğŸ‡ Amino Acid PET**: Offers more specific imaging for brain tumors as they tend to uptake amino acids at a higher rate.
     - **ğŸ Choline-PET**: Utilized for recurrent gliomas due to elevated choline metabolism in these tumors.
   - **ğŸ’‰ Therapeutic**:
     - **ğŸ›¡ï¸ Radiolabeled antibodies**: Specially designed to target specific markers on brain tumor cells.
     - **ğŸ”¥ BNCT (Boron Neutron Capture Therapy)**: An experimental technique that relies on the uptake of boron by tumor cells, followed by neutron irradiation, causing cell death.

7. **ğŸ‡ Lymphomas**
   - **ğŸ” Diagnostic**:
     - **ğŸ¬ FDG-PET**: Extremely beneficial for the staging of lymphomas, monitoring treatment responses, and detecting relapses.
   - **ğŸ’‰ Therapeutic**:
     - **ğŸ›¡ï¸ Radiolabeled antibodies**: These target specific cells of the lymphatic system, delivering targeted radiation.

8. **ğŸ¦´ Bone Metastases**
   - **ğŸ” Diagnostic**:
     - **ğŸª¶ Bone Scintigraphy**: Uses Tc-99m labeled diphosphonates to image areas of bone remodeling commonly associated with metastases.
   - **ğŸ’‰ Therapeutic**:
     - **âš›ï¸ Radium-223**: Specifically targets bone metastases arising from prostate cancer.
     - **ğŸŒŸ Samarium-153/Strontium-89**: These radionuclides preferentially localize to areas of bone metastases, providing pain relief by emitting beta radiation.

### ğŸ›¡ï¸ **Radiolabeled Antibodies in Nuclear Medicine**

1. **ğŸ¬ FDG (Fluorodeoxyglucose)**
   - Though not an antibody, FDG is a glucose analog radiolabeled with Fluorine-18. It's mainly used in PET imaging to detect and monitor various cancers based on their metabolic activity.

2. **ğŸ§¬ Rituximab**
   - **Radiolabel**: Commonly labeled with Yttrium-90 (Y-90) or Iodine-131 (I-131).
   - **Target**: CD20 antigen on B-lymphocytes.
   - **Usage**: Mainly for non-Hodgkin's lymphoma.

3. **ğŸ§ª Trastuzumab (Herceptin)**
   - **Radiolabel**: Commonly labeled with Zirconium-89 (Zr-89) for PET imaging.
   - **Target**: HER2/neu receptor.
   - **Usage**: For HER2-positive breast cancers.

4. **ğŸŒ Cetuximab**
   - **Radiolabel**: Labeled with Copper-64 (Cu-64) for diagnostic purposes.
   - **Target**: Epidermal growth factor receptor (EGFR).
   - **Usage**: Colorectal and head and neck cancers.

5. **ğŸ’¡ Tositumomab (Bexxar)**
   - **Radiolabel**: Iodine-131 (I-131).
   - **Target**: CD20 antigen on B-lymphocytes.
   - **Usage**: Non-Hodgkin's lymphoma.

6. **ğŸ”¥ Ibritumomab Tiuxetan (Zevalin)**
   - **Radiolabel**: Yttrium-90 (Y-90) or sometimes Indium-111 (In-111) for dosimetry or imaging.
   - **Target**: CD20 antigen on B-lymphocytes.
   - **Usage**: Non-Hodgkin's lymphoma.

7. **ğŸŒ€ PSMA-targeted antibodies**
   - **Radiolabel**: Gallium-68 (Ga-68) for PET imaging and Lutetium-177 (Lu-177) for therapeutic purposes.
   - **Target**: Prostate-specific membrane antigen.
   - **Usage**: Prostate cancer.

8. **ğŸŒŒ Immuno-PET using various antibodies**
   - **Radiolabel**: Zirconium-89 (Zr-89) is a popular choice due to its long half-life suitable for the pharmacokinetics of antibodies.
   - **Target & Usage**: Various targets depending on the antibody in question. Immuno-PET has been explored for imaging immune processes in real-time and has potential applications in several cancers.


## ğŸ’“ **Nuclear Cardiology: An In-depth Dive**

### **1ï¸âƒ£ Diagnostic Modalities and Techniques**

**A. Myocardial Perfusion Imaging (MPI)**

- **What is it?** MPI evaluates blood flow to the heart muscle (myocardium) both at rest and during stress.
  
- **Why is it important?** MPI helps detect areas of the myocardium that have reduced blood flow, which could be due to blocked arteries or previous heart attacks.

- **Procedure**: Patients typically undergo two sets of scans: one at rest and one after stress (either exercise or pharmacological stress). A gamma camera captures images of the distribution of the radiotracer in the heart.

**B. Radionuclide Angiography (RNA, MUGA Scan)**

- **What is it?** A test that uses radiotracers to visualize the movement of the heart chambers and assess the function of the heart, especially the ejection fraction.

- **Applications**: It's widely used to monitor patients receiving cardiotoxic chemotherapy to ensure the heart remains healthy.

**C. Ventriculography**

- **What is it?** It evaluates the shape and movement of the heart's ventricles.

**D. PET Cardiac Imaging**

- **What is it?** PET can provide higher-resolution images and quantitative myocardial blood flow measurements, offering more detailed insights than traditional SPECT scans.

### **2ï¸âƒ£ Common Radiopharmaceuticals**

**A. Thallium-201 (Tl-201)**

- **Usage**: Primarily for MPI.
- **Mechanism**: Tl-201 acts as a potassium analog and is taken up by viable heart cells. Areas of the heart with decreased perfusion take up less Tl-201.

**B. Technetium-99m (Tc-99m) agents** 

- Examples include Tc-99m sestamibi (Cardiolite) and Tc-99m tetrofosmin.
- **Usage**: Primarily for MPI.
- **Mechanism**: These agents are taken up by viable heart cells and provide good image quality with relatively low radiation exposure.

**C. Rubidium-82 (Rb-82)**

- **Usage**: For PET myocardial perfusion imaging.
- **Mechanism**: It's a potassium analog and gets taken up by viable myocardial cells.

### **3ï¸âƒ£ Applications of Nuclear Cardiology**

**A. Coronary Artery Disease (CAD)**

- Detecting CAD, evaluating its severity, and determining its prognosis.

**B. Heart Failure**

- Evaluating the cause and determining treatment strategies.
  
**C. Cardiomyopathies**

- Differentiating between ischemic and non-ischemic cardiomyopathies.

**D. Pre-operative Risk Stratification**

- Assessing patients undergoing non-cardiac surgery, especially if they have multiple cardiovascular risk factors.

### **4ï¸âƒ£ Innovations and Future Perspectives**

**A. Hybrid Imaging**

- Combining modalities like SPECT/CT or PET/CT for better localization and characterization of cardiac findings.

**B. Artificial Intelligence in Cardiac Imaging**

- Using AI algorithms to assist in image interpretation, quantification, and even prognosis prediction.

**C. Newer Radiotracers**

- Exploring novel radiopharmaceuticals for better specificity and lower radiation doses.


## â¤ï¸ **Nuclear Cardiology: Illuminating the Heart's Function and Pathology**

### **1ï¸âƒ£ Myocardial Perfusion Imaging (MPI) with SPECT ğŸ“¸**

MPI is primarily used to detect areas of the heart that aren't receiving enough blood, which can be indicative of coronary artery disease.

**A. Stable Coronary Artery Disease (CAD)**

- **Stress phase**: Decreased uptake in the region supplied by a stenotic coronary artery, manifesting as a perfusion defect.
- **Rest phase**: The perfusion defect might improve or normalize, indicating viable myocardium (ischemia).

**B. Myocardial Infarction (Heart Attack)**

- **Stress and Rest phases**: Persistent decreased uptake or a defect in both phases, indicating an area of infarction (non-viable myocardium).

**C. Multi-Vessel Disease**

- **Stress phase**: Multiple areas of decreased uptake, often in territories of different coronary arteries.

### **2ï¸âƒ£ PET in Cardiology ğŸ“¸**

**A. Myocardial Viability Assessment**

- **FDG-PET**: Areas with decreased perfusion but preserved FDG uptake suggest hibernating myocardium, which is still viable but functionally impaired.

**B. Inflammation and Infection**

- **FDG-PET**: Increased uptake can be observed in cases of cardiac sarcoidosis or endocarditis, indicating active inflammation or infection.

### **3ï¸âƒ£ Radionuclide Ventriculography (MUGA/RNV)**

This evaluates the pumping function of the heart.

**A. Heart Failure**

- Decreased ejection fraction indicates reduced heart pumping efficiency.

### **4ï¸âƒ£ Innovations and Future Directions ğŸŒŸ**

**A. Amyloid Cardiomyopathy Imaging**

- **Bone tracers (e.g., DPD, PYP, HMDP)**: Enhanced uptake in the heart can be indicative of cardiac amyloid deposition.

**B. Sympathetic Innervation Imaging**

- **I-123 MIBG**: Helps in assessing the integrity of cardiac sympathetic innervation. Reduced heart-to-mediastinum ratio indicates abnormal sympathetic function, seen in conditions like heart failure or certain arrhythmias.

**C. Plaque Imaging**

- **FDG-PET and other novel tracers**: Targeting active atherosclerotic plaques. Increased uptake can indicate inflamed or vulnerable plaques at risk for rupture.


## ğŸ§  **Nuclear Neurology: Unlocking the Brain's Secrets**

### **1ï¸âƒ£ Diagnostic Modalities and Techniques**

**A. Positron Emission Tomography (PET) Brain Imaging ğŸ“¸**

- **What is it?** PET is a primary modality in neurology, providing insights into brain metabolism, perfusion, and neurotransmitter activity.
- **Applications**:
  - **Cognitive Disorders**: Alzheimer's, Frontotemporal dementia, etc.
  - **Movement Disorders**: Parkinson's disease and its variants.
  - **Epilepsy**: Localization of seizure foci for potential surgical intervention.

**B. Single Photon Emission Computed Tomography (SPECT) Brain Imaging ğŸ“¸**

- **What is it?** SPECT offers cerebral perfusion images.
- **Applications**: 
  - **Stroke**: Differentiating between ischemic and hemorrhagic stroke.
  - **Traumatic Brain Injury (TBI)**: Assessing perfusion abnormalities.

### **2ï¸âƒ£ Common Radiopharmaceuticals**

**A. Fluorodeoxyglucose (FDG)**

- **Usage**: As a glucose analog, FDG evaluates brain metabolism.
- **Applications**: Alzheimer's disease shows decreased uptake in the parietotemporal and posterior cingulate cortex. Epilepsy foci may show decreased uptake interictally.

**B. Amyloid Imaging Agents (e.g., Florbetapir, Florbetaben, Flutemetamol)**

- **Usage**: Detect beta-amyloid plaques in the brain, a hallmark of Alzheimer's disease.

**C. Dopamine Transporter Imaging Agents (e.g., DaTSCAN â€“ Ioflupane I-123)**

- **Usage**: Assess the integrity of dopaminergic neurons in the brain.
- **Applications**: Differentiate between Parkinson's disease (reduced uptake) and essential tremor (normal uptake).

**D. Radiolabeled Compounds for Neurotransmitter Imaging**

- Agents like C-11 raclopride target dopamine receptors, helping in research and sometimes in clinical scenarios to evaluate the dopamine system.

### **3ï¸âƒ£ Applications of Nuclear Neurology**

**A. Dementia and Cognitive Impairment**

- Differentiating between various dementia types based on metabolic patterns and amyloid imaging.

**B. Movement Disorders**

- Evaluating Parkinson's disease, multiple system atrophy, progressive supranuclear palsy, and other conditions based on neurotransmitter and metabolic imaging.

**C. Epilepsy**

- Localizing seizure foci for potential surgery and assessing the potential outcomes post-surgery.

**D. Psychiatric Disorders**

- Research into conditions like schizophrenia, depression, and obsessive-compulsive disorder has benefited from neurotransmitter imaging.

### **4ï¸âƒ£ Innovations and Future Perspectives**

**A. Tau Imaging ğŸ§©**

- With agents like flortaucipir, we can now image tau tangles, another key pathological feature of Alzheimer's.

**B. Integration with MRI ğŸ”„**

- Combining PET or SPECT with MRI (PET-MRI) offers high-resolution anatomical data with metabolic or molecular insights.

**C. AI and Advanced Image Analysis ğŸ–¥ï¸**

- AI algorithms aid in more precise quantification, diagnostics, and potentially prognosis prediction.

**D. Theranostics in Neurology âš•ï¸**

- Leveraging radiopharmaceuticals both for diagnosis and potential targeted therapy.


## ğŸ§  **Nuclear Neurology: Mapping Brain Activity and Dysfunction**

### **1ï¸âƒ£ PET Brain Imaging Patterns ğŸ“¸**

**A. Alzheimer's Disease**

- **FDG-PET**: Decreased uptake in the parietotemporal regions, posterior cingulate cortex, and eventually, the frontal cortex.
- **Amyloid-PET**: Increased deposition of amyloid-beta plaques, especially in the cortex.

**B. Frontotemporal Dementia**

- **FDG-PET**: Decreased uptake in the frontal and/or anterior temporal lobes.

**C. Lewy Body Dementia**

- **FDG-PET**: Decreased uptake in the occipital lobes, often with a relative preservation of the posterior cingulate cortex (the "cingulate island sign").

**D. Parkinson's Disease**

- **FDG-PET**: Can show decreased uptake in the parietal cortex, which correlates with cognitive dysfunction.
- **DaTSCAN**: Reduced striatal binding, especially in the posterior putamen.

**E. Epilepsy**

- **FDG-PET (interictal)**: Hypometabolism in the region of seizure onset.
- **FDG-PET (ictal)**: Hypermetabolism can sometimes be seen in the seizure focus.

### **2ï¸âƒ£ SPECT Brain Imaging Patterns ğŸ“¸**

**A. Ischemic Stroke**

- **Perfusion SPECT**: Decreased perfusion in the affected territory corresponding to the vascular distribution.

**B. Traumatic Brain Injury**

- **Perfusion SPECT**: Can show diffuse or focal perfusion defects, often not corresponding to anatomical damage.

### **3ï¸âƒ£ Neurotransmitter and Receptor Imaging**

**A. Schizophrenia**

- **Dopamine D2 receptor imaging**: Increased binding in the striatum suggesting overactivity of the dopaminergic pathways.

**B. Depression**

- **Serotonin receptor imaging**: Altered serotonin receptor binding, potentially indicating dysfunction in serotonergic pathways.

### **4ï¸âƒ£ Innovations and Future Directions**

**A. Tau Imaging ğŸ§©**

- In Alzheimer's Disease: Shows increased deposition of tau tangles, especially in the temporal lobes and other cortical regions.

**B. Glutamate Receptor Imaging**

- Being researched for conditions like schizophrenia and mood disorders. Patterns aren't as well-defined yet, but abnormalities in glutamate signaling are thought to play a role in several neuropsychiatric disorders.

**C. Neuroinflammation Imaging**

- Imaging markers of inflammation like TSPO can be indicative of active neuroinflammation seen in conditions like multiple sclerosis or after acute events like a stroke.



## ğŸ’€ **Nuclear Orthopedics: Probing the Bones and Joints**

Nuclear medicine provides critical insights into various orthopedic conditions by visualizing bone metabolism, inflammation, and blood flow. Let's explore the major applications and how they manifest in nuclear imaging.

### **1ï¸âƒ£ Bone Scintigraphy (Bone Scan) with Tc-99m MDP or HDP ğŸ“¸**

This imaging technique is based on the uptake of radiopharmaceuticals in regions of increased bone turnover.

**A. Fractures**

- **Acute**: Increased radiotracer uptake at the fracture site due to heightened osteoblastic activity and increased blood flow.
- **Stress fractures**: Often seen in athletes, there's a localized increase in uptake, even if X-rays are negative initially.

**B. Osteoarthritis**

- Joints affected by osteoarthritis (OA) display increased uptake due to bone remodeling associated with the degenerative process.

**C. Osteomyelitis (Bone Infection)**

- Intense, localized uptake in the early phase and delayed images. This pattern helps differentiate from conditions like cellulitis, which may not show the same delayed uptake.

**D. Bone Tumors and Metastases**

- **Primary bone tumors**: Varied uptake, depending on the type of tumor. Osteosarcoma, for instance, often shows intense uptake.
- **Bone metastases**: In conditions like prostate or breast cancer, increased uptake in multiple spots might be seen, indicating metastatic spread.

### **2ï¸âƒ£ White Blood Cell (WBC) Scintigraphy ğŸ©¸**

Labeled WBCs are used to detect sites of inflammation or infection, especially in complex cases where bone scans might be non-specific.

**A. Diabetic Foot**

- Helps in differentiating soft tissue infections from osteomyelitis. Increased uptake in bones in delayed images suggests osteomyelitis.

**B. Prosthetic Joint Infections**

- In suspected joint infections post-arthroplasty, increased uptake around the prosthetic joint can be a critical indicator.

### **3ï¸âƒ£ SPECT/CT in Orthopedics ğŸ”**

SPECT/CT combines functional data from SPECT with anatomical data from CT, which can be invaluable in orthopedics.

**A. Localization in Complex Anatomy**

- Regions like the spine, where anatomy is intricate, SPECT/CT aids in pinpointing the exact vertebra or disc with pathology.

### **4ï¸âƒ£ Emerging Techniques and Innovations ğŸŒŸ**

**A. PET in Orthopedics**

- **FDG-PET**: While primarily used for oncologic imaging, FDG-PET is being explored for conditions like chronic osteomyelitis, sarcoidosis-related arthritis, and in some bone tumors.

**B. New Radiotracers**

- Agents targeting specific receptors or processes related to bone metabolism or inflammation are under research.


## ğŸ¦  **Nuclear Imaging in Infection Detection**

### **1ï¸âƒ£ Bone Scintigraphy (Bone Scan) with Tc-99m MDP or HDP ğŸ¦´**

While primarily used for orthopedic indications, bone scans can also detect bone infections.

- **Osteomyelitis**: There's typically an intense uptake at the infection site due to increased bone turnover and blood flow. Distinguishing between acute osteomyelitis and other conditions like cellulitis is possible based on uptake patterns.

### **2ï¸âƒ£ White Blood Cell (WBC) Scintigraphy ğŸ©¸**

**A. Direct Labeling Methods**: In this technique, a patient's white blood cells are extracted, labeled with a radiopharmaceutical, and then re-injected into the patient.

- **Indications**:
  - **Osteomyelitis**: Especially in patients with diabetic foot ulcers, to differentiate soft tissue infection from bone infection.
  - **Febrile Neutropenia**: In patients with cancer and reduced white blood cell counts, to detect hidden infection sites.
  - **Prosthetic Joint Infections**: To detect infections in recently implanted joints.
  
**B. Indirect Labeling Methods**: Uses agents like **Sulesomab**, a radiolabeled monoclonal antibody fragment targeting the granulocyte receptor.

### **3ï¸âƒ£ Gallium-67 Scans ğŸª€**

**Gallium-67** citrate binds to transferrin and is taken up by inflammatory cells. It's less commonly used now due to longer scanning times and the development of newer agents.

- **Indications**:
  - **Pulmonary Infections**: Including lung abscesses, pneumonia, and opportunistic infections in immunocompromised patients.
  - **Abdominal Infections**: Abscesses or inflammatory conditions.
  - **Chronic Infections**: Like tuberculosis or sarcoidosis.

### **4ï¸âƒ£ FDG-PET Imaging ğŸŒŸ**

FDG-PET, traditionally used for oncologic imaging, is gaining ground in infection imaging because inflammatory cells, like neutrophils and activated macrophages, also take up FDG.

- **Indications**:
  - **Chronic Osteomyelitis**: Especially in challenging anatomical regions.
  - **Fever of Unknown Origin**: When the source of fever remains elusive, FDG-PET can help locate hidden infections or inflammatory foci.
  - **Vascular Graft Infections**: To identify infected grafts.
  
### **5ï¸âƒ£ Radiolabeled Antibiotic Scans ğŸ’Š**

Antibiotics like ciprofloxacin can be radiolabeled and used for imaging, especially targeting bacterial infections directly. However, they're more experimental compared to the established techniques above.



[Back to top](#nuclear-medicine-cheatsheet)

## Therapeutic Applications

### ğŸŒŒ **Radioiodine Therapy (I-131) in Depth**

#### ğŸ§ª **Molecular Makeup**:
- **Iodine-131 (I-131)** is a radioactive isotope of iodine. It decays by beta and gamma emission. The beta radiation is therapeutic, while the gamma emission allows for imaging and dosimetry assessment. Its half-life is approximately 8 days.

#### ğŸ’¡ **Basic Principle**:
Iodine, as an element, has a natural affinity for the thyroid gland. The thyroid cells take up iodine as a part of the hormone production process. Because I-131 is a radioactive form of iodine, the thyroid cells cannot distinguish it from the non-radioactive iodine. When ingested, it gets concentrated in the thyroid gland, where it emits radiation, thereby damaging or killing the cells.

#### ğŸ“Œ **Applications**:

1. **Thyroid Cancer** ğŸ¦ :
   - **Post-surgical ablation**: After surgery (thyroidectomy) for thyroid cancer, I-131 is used to destroy any remaining thyroid tissue or microscopic disease that might not have been surgically removed. This not only ensures eradication of residual thyroid cancer cells but also enables clearer follow-up scans (since normal thyroid tissue can uptake iodine and create 'noise' on the scans).
   
   - **Treatment of metastatic disease**: Some patients with thyroid cancer may develop metastases (spread of cancer) to other parts of the body. If these metastatic cells continue to take up iodine, they can be treated with I-131.
   
   - **Follow-up and Surveillance**: I-131 is also used in smaller doses for whole-body scans to check for the presence of any residual or recurrent disease.

2. **Hyperthyroidism** ğŸŒ¡ï¸:
   - **Graves' Disease**: This is an autoimmune condition where the thyroid becomes overactive. I-131 is used to reduce the activity of the thyroid gland.
   
   - **Toxic Nodular Goiter**: Sometimes, one or more nodules (lumps) in the thyroid can become overactive. I-131 can be used to target and reduce the function of these nodules.
   
   - **Treatment Process**: The patient ingests I-131 orally, usually as a capsule or liquid. Over time, the I-131 targets the hyperactive thyroid cells, reducing or normalizing their activity.

#### ğŸ›¡ï¸ **Safety and Precautions**:
- **Isolation**: After receiving a therapeutic dose of I-131, patients might be required to stay in the hospital in isolation for a few days to ensure that others aren't exposed to radiation. This is especially the case for high doses used in cancer treatment.
  
- **Home Precautions**: After discharge, patients might be advised to follow certain precautions at home, like sleeping alone, maintaining distance from pregnant women and children, and using separate bathroom facilities when possible.
  
- **Side Effects**: Temporary side effects can include salivary gland swelling, dry mouth, taste changes, and nausea. There's also a small risk of developing a new, non-thyroidal cancer later in life due to the radiation, but this risk is generally considered lower than the benefits of the treatment for the targeted conditions.



### **2ï¸âƒ£ Radionuclide Pain Palliation for Bone Metastases ğŸ¦´**

This therapeutic method involves using radionuclides that have an affinity for the bone, especially areas of increased bone turnover seen in bone metastases. Bone-seeking radionuclides help provide pain relief in patients with metastatic bone disease. The mechanism of action is based on the radiation emitted from these radionuclides, which results in localized irradiation of metastatic lesions, reducing tumor size and, consequently, relieving pain.

**A. Strontium-89 (Sr-89) Chloride ğŸ§¬** 
- **Molecular Makeup**: Strontium-89 is a beta-emitting radionuclide.
- **Mechanism**: Strontium behaves similarly to calcium, so it's taken up by bone, particularly in areas with increased bone turnover like metastatic sites.
- **Applications**: Used for pain palliation in metastatic bone disease, especially in prostate and breast cancers.

**B. Samarium-153 (Sm-153) Lexidronam (EDTMP) ğŸ§¬** 
- **Molecular Makeup**: Samarium-153 is a beta-emitting radionuclide, chelated to EDTMP, a bone-seeking molecule.
- **Mechanism**: The EDTMP component directs the radionuclide to the bone, especially sites of active turnover.
- **Applications**: Pain relief for patients with osteoblastic bone metastases.

**C. Radium-223 (Ra-223) Dichloride ğŸ§¬** 
- **Molecular Makeup**: Radium-223 is an alpha-emitting radionuclide.
- **Mechanism**: Radium is a calcium mimetic and, therefore, taken up by bone. The significant aspect of using an alpha-emitter in this context is that alpha particles have a higher linear energy transfer compared to beta particles. This results in more localized damage, which is optimal for micro-metastatic disease. The range of alpha particles in tissues is short (a few cell diameters), which spares the surrounding healthy tissue.
- **Applications**: Used for the treatment of metastatic castration-resistant prostate cancer with symptomatic bone metastases and no known visceral metastatic disease.



### ğŸ¯ **Peptide Receptor Radionuclide Therapy (PRRT)**
Peptide Receptor Radionuclide Therapy (PRRT) is an innovative and targeted treatment approach primarily aimed at managing neuroendocrine tumors (NETs). PRRT utilizes specific peptides conjugated to radionuclides, offering both diagnostic and therapeutic applications. 

#### **1ï¸âƒ£ The Science Behind PRRT ğŸ§ª**
- **Mechanism**: The basic principle revolves around exploiting the overexpression of certain receptors on tumor cells, such as the somatostatin receptors on NETs. By combining a radionuclide with a peptide that has a high affinity for these receptors, PRRT can selectively deliver radiation to the tumor cells while sparing healthy tissues.

- **Radiopharmaceuticals**: These are molecules that comprise both a targeting moiety (typically a peptide) and a therapeutic radioactive component. 

#### **2ï¸âƒ£ Lutetium-177 (Lu-177) DOTATATE ğŸ§¬**
- **What is it?**: Lu-177 DOTATATE combines the radioactive isotope Lutetium-177 with DOTATATE, a peptide that binds with high specificity to somatostatin receptors prevalent on NET cells.
  
- **How it works?**: Once injected into the bloodstream, Lu-177 DOTATATE travels and binds to NETs that express somatostatin receptors. This binding results in the delivery of targeted radiation, primarily beta emission, to the tumor, causing DNA damage and subsequent tumor cell death.

- **Applications**:
  - **Treatment of NETs**: Especially beneficial for inoperable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
  - **Imaging**: It can also be used for imaging purposes to identify the location and extent of NETs before therapy.
  
#### **3ï¸âƒ£ Advantages and Challenges âœ…âŒ**
- **Advantages**:
  - **Targeted Treatment**: PRRT offers a more precise approach by focusing radiation delivery to the tumor sites, minimizing collateral damage to healthy tissues.
  - **Extended Survival**: Studies have shown prolonged progression-free survival and improved quality of life for patients treated with PRRT.
  - **Combination Therapy**: PRRT can be combined with other treatments, including chemotherapy, offering synergistic effects.

- **Challenges**:
  - **Limited to Receptor-positive Tumors**: Only effective for tumors expressing the targeted receptors.
  - **Side Effects**: While it's more targeted, PRRT isn't without side effects. Patients might experience kidney damage, hematological abnormalities, and other transient symptoms.
  - **Cost**: Being a relatively new and specialized therapy, PRRT can be expensive.

#### **4ï¸âƒ£ Future of PRRT ğŸŒŸ**
As research progresses, the horizon of PRRT is expanding beyond NETs. Scientists are exploring the potential of other peptides targeting different receptors for a wider array of cancers. New radionuclides are also under investigation to optimize the therapeutic outcomes and minimize side effects.


### ğŸ¦  **PSMA Therapy for Prostate Cancer**

Prostate cancer is the second most common cancer in men globally. As the disease progresses, it may become resistant to conventional treatments, and metastases can develop. One of the significant advancements in treating metastatic prostate cancer has been the development of therapies targeting Prostate-Specific Membrane Antigen (PSMA).

#### **ğŸ§¬ What is PSMA?**

PSMA is a cell surface protein that is overexpressed in prostate cancer cells, especially in higher-grade tumors and metastatic sites. Its overexpression in prostate cancer and limited expression in normal tissues make it an ideal target for diagnostic imaging and therapeutic interventions.

#### **ğŸŒŸ Lutetium-177 (Lu-177) PSMA**

**1ï¸âƒ£ Molecular Makeup and Mechanism:**

- **Lutetium-177**: It's a beta-emitting radionuclide. When attached to a molecule that can target cancer cells, the emitted radiation can kill those cells.

- **PSMA Ligands**: These are molecules specifically designed to bind to PSMA on the surface of prostate cancer cells. When radiolabeled with Lu-177, they deliver the radionuclide directly to the tumor, minimizing damage to surrounding healthy tissues.

**2ï¸âƒ£ Therapeutic Procedure:**

- **Administration**: Lu-177 PSMA is given intravenously. Once in the bloodstream, the PSMA ligands seek out prostate cancer cells and bind to the PSMA on their surface.

- **Targeted Radiation**: The bound Lu-177 emits beta radiation, which has a relatively short range. This means that the radiation affects the cancer cell and its immediate surroundings, minimizing collateral damage.

**3ï¸âƒ£ Applications:**

- **Metastatic Castration-Resistant Prostate Cancer (mCRPC)**: This is an advanced form of prostate cancer that no longer responds to hormonal therapies. Lu-177 PSMA has shown promising results in treating mCRPC, especially in patients who have exhausted other treatment options.

- **Biochemical Recurrence**: In patients who have had a prostatectomy or radiation therapy, a rising PSA level (with no detectable disease on conventional imaging) suggests a recurrence at the molecular level. Lu-177 PSMA can target these microscopic disease sites.

**4ï¸âƒ£ Benefits and Outcomes:**

- **Prolonged Survival**: Several studies have shown that Lu-177 PSMA can prolong survival in patients with mCRPC.

- **Quality of Life**: Reduced pain, improved general well-being, and better control of urinary symptoms have been reported.

- **Biochemical Response**: A significant number of patients show a substantial drop in PSA levels, indicating a positive response to the therapy.

**5ï¸âƒ£ Side Effects and Considerations:**

- **Xerostomia**: Dry mouth due to the uptake of PSMA agents in the salivary glands.

- **Bone Marrow Suppression**: Reduced production of blood cells can occur, necessitating regular blood count monitoring.

- **Nephrotoxicity**: Kidney function needs to be monitored, given the renal excretion of the agent.

### ğŸ¯ **Radioimmunotherapy (RIT) in Detail**

#### **Overview**

Radioimmunotherapy (RIT) harnesses the specificity of antibodies to deliver targeted radiation to malignant cells. In essence, it combines the precise targeting capability of monoclonal antibodies with the cytotoxic power of radiation, allowing for the targeted destruction of cancer cells with minimal impact on surrounding healthy tissue.

#### **Mechanism of Action**

1. **Antibody Selection**: A monoclonal antibody (mAb) is chosen based on its ability to bind specifically to a particular antigen that's commonly expressed on the surface of the tumor cells of interest.
2. **Radiolabeling**: The selected mAb is then conjugated or "labeled" with a radioactive isotope. This radioactive tagging allows the mAb to deliver targeted radiation directly to the tumor cells.
3. **Administration**: The radiolabeled antibody is then administered, typically intravenously. Once in the bloodstream, the antibody seeks out and binds to the tumor cells expressing the target antigen.
4. **Targeted Radiation**: Upon binding, the radioactive isotope emits radiation that damages the DNA of the tumor cell, leading to cell death. Due to the targeted nature of the delivery, radiation exposure to non-tumor cells is minimized.

#### **Main Players in RIT**

1. **Ibritumomab Tiuxetan (Zevalin) ğŸ§ª**
   - **Radiolabel**: Yttrium-90 (Y-90)
   - **Target Antigen**: CD20
   - **Indication**: Used predominantly for non-Hodgkin's lymphoma, especially for patients who don't respond to conventional treatment or for those in relapse.
   - **Process**: The patient first receives a non-radioactive dose of rituximab to clear out excess CD20 antigens. This is followed by the administration of Zevalin.
   
2. **Tositumomab (Bexxar) ğŸ§ª**
   - **Radiolabel**: Iodine-131 (I-131)
   - **Target Antigen**: CD20
   - **Indication**: Similar to Zevalin, Bexxar is used for certain types of non-Hodgkin's lymphoma.
   - **Process**: The patient receives a non-radioactive dose of tositumomab followed by the radiolabeled version.

#### **Benefits and Challenges**

- **Benefits**:
  1. **Targeted Delivery**: RIT delivers radiation directly to tumor cells, reducing collateral damage to healthy cells.
  2. **Overcomes Resistance**: Effective in treating cancers that might be resistant to standard radiation or chemotherapy.
  3. **Combinatorial Approach**: Can be combined with other therapies for a synergistic effect.

- **Challenges**:
  1. **Bone Marrow Suppression**: The main toxicity concern. This is due to radiation affecting bone marrow cells, which can lead to decreased blood cell counts.
  2. **Potential for Allergic Reactions**: As with any antibody therapy, there's a risk of allergic reactions.
  3. **Limited to Cancers with Known Antigens**: The efficacy of RIT is dependent on the presence of targetable antigens on cancer cells. 



### **6ï¸âƒ£ Liver Cancer Treatments using Yttrium-90 (Y-90) Microspheres**

#### **Background ğŸŒ**

Liver cancers, both primary (like hepatocellular carcinoma or cholangiocarcinoma) and secondary (metastases from other primary tumors), are a significant healthcare burden. While surgery, chemotherapy, and other treatments have their place, there's a need for localized therapies, especially for tumors that are unresectable. This is where Y-90 microspheres come into play.

#### **The Y-90 Isotope ğŸ§ª**

Yttrium-90 is a beta-emitting isotope. The emitted beta radiation has a relatively short range, making it ideal for delivering targeted radiation to liver tumors while sparing the surrounding healthy liver tissue.

#### **The Procedure ğŸ¥**

**A. Pre-treatment Work-up ğŸ“‹**

1. **Mapping Angiogram**: This helps identify the liver's arterial anatomy and any potential routes the microspheres could take that might lead them away from the liver.
2. **Technetium-99m macroaggregated albumin (Tc-99m MAA) scan**: This scan is done after injecting a non-radioactive substance to mimic how the Y-90 microspheres will distribute in the liver. It helps to estimate the radiation dose to the tumor and surrounding liver tissue and ensures no significant shunting to the lungs.

**B. Treatment Procedure ğŸ©º**

1. **Catheter Insertion**: A catheter is introduced via the femoral artery in the groin, navigated into the hepatic artery supplying the liver.
2. **Microsphere Administration**: The Y-90 microspheres are infused through the catheter into the liver's arterial blood supply. Since the liver tumors get their blood mainly from the hepatic artery, this allows for targeted delivery of radiation to the tumors.
3. **Post-procedure Imaging**: Sometimes, post-therapy imaging is performed to confirm the distribution of microspheres.

#### **Types of Y-90 Microspheres ğŸ¦ **

There are two commercially available Y-90 microsphere products:

1. **SIR-SpheresÂ®**: These are resin-based microspheres. Their relatively small size allows for deeper penetration into the tumor tissue.
2. **TheraSphereÂ®**: These are glass-based microspheres, a bit larger than the resin-based type.

#### **Applications ğŸ¯**

1. **Primary Liver Cancers**: Particularly hepatocellular carcinoma, when surgery or transplantation isn't an option.
2. **Metastatic Liver Cancers**: Especially metastases from colorectal cancer that are resistant to chemotherapy.

#### **Benefits and Challenges âš–ï¸**

**Benefits**:
- **Targeted Therapy**: The localized radiation helps in sparing healthy liver tissue.
- **Bridge to Transplant**: Can be used to keep the tumor under control while a patient waits for a liver transplant.
- **Combination with Chemotherapy**: Can be combined with systemic therapies for a synergistic effect.

**Challenges**:
- **Potential Side Effects**: Like radiation-induced liver disease, gastrointestinal ulceration (if microspheres get into the stomach or duodenal blood supply), or fatigue.
- **Technical Complexity**: Requires expertise in interventional radiology.



#### **SIR-SpheresÂ®**

**Physical Attributes**:

- **Material**: Resin-based.
- **Size**: The microspheres have an average diameter of approximately 32 micrometers (range 20-60 micrometers).
- **Activity**: Each microsphere contains a specific activity which varies based on the treatment planning.

**Advantages**:

1. **Deeper Penetration**: Due to their smaller size, SIR-Spheres can travel deeper into the smaller arterioles of the tumor, potentially delivering the therapeutic radiation dose more uniformly throughout the tumor tissue.
2. **Versatility**: Suitable for a variety of liver tumors, both primary and secondary (metastatic).

**Disadvantages**:

1. **Radiation to Lungs**: If there's arteriovenous shunting in the liver, there might be a higher risk of some of the microspheres reaching the lungs, potentially causing radiation pneumonitis.
2. **Higher Number of Spheres**: While this allows for more uniform distribution, it also means that there's a higher absolute number of spheres that must be infused, potentially increasing procedure time.

---

#### **TheraSphereÂ®**

**Physical Attributes**:

- **Material**: Glass-based.
- **Size**: The microspheres are larger, with an average diameter of about 20 to 30 micrometers.
- **Activity**: Each microsphere has a higher specific activity, meaning each individual sphere emits more radiation than its resin-based counterpart.

**Advantages**:

1. **Higher Specific Activity**: The higher radioactive content per microsphere can mean fewer spheres are needed for a given dose, potentially shortening the delivery time.
2. **Lower Risk to Lungs**: The slightly larger size might reduce the risk of the spheres traveling to the lungs through arteriovenous shunts.

**Disadvantages**:

1. **Limited Depth of Penetration**: Their larger size might limit the depth of penetration into tumor tissue, potentially resulting in less uniform radiation distribution.
2. **Risk of Non-target Embolization**: Due to their size and the way they are administered, there could be a risk of non-target embolization, which means they could block blood vessels that weren't intended to be blocked.


### â˜¢ï¸ **Phosphorus-32 (P-32) Therapy**

#### **Molecular Composition & Characteristics ğŸ§ª**

- **Isotope**: Phosphorus-32 (P-32) is a beta-emitting radionuclide with a half-life of 14.29 days.
  
- **Nature**: As an isotope of phosphorus, P-32 behaves similarly to its stable counterpart, Phosphorus-31, which is a natural component of the human body, especially in the bones and ATP (adenosine triphosphate) in cells.

- **Radioactive Decay**: P-32 decays by beta emission, resulting in the production of Sulphur-32 (a stable isotope). The emitted beta particles interact with tissues and cause localized damage, which is useful for therapeutic purposes.

#### **Clinical Applications ğŸ©º**

1. **Polycythemia Vera (PV) ğŸ¦ **

   - **Condition**: Polycythemia Vera is a type of blood cancer where the bone marrow produces too many red blood cells. This can thicken the blood, slowing its flow, which might lead to clotting.

   - **Treatment Mechanism with P-32**: When P-32 is introduced into the body, it gets selectively taken up by the bone marrow. The emitted beta particles from the decaying P-32 target the overactive bone marrow cells, reducing the overproduction of red blood cells.
     
   - **Administration**: It is usually given orally as sodium phosphate P-32 solution.

2. **Pleural or Peritoneal Effusion due to Malignancies ğŸ©¸**

   - **Condition**: These effusions are accumulations of fluid in the pleural cavity (around the lungs) or the peritoneal cavity (in the abdomen), often due to cancers.

   - **Treatment Mechanism with P-32**: P-32 can be instilled into the pleural or peritoneal cavities. The radioactive emissions target and destroy malignant cells present in the effusion, controlling the spread and recurrence of the fluid accumulation.
     
   - **Administration**: For this application, P-32 is introduced directly into the effusion fluid in the form of chromic phosphate P-32 suspension.

#### **Safety & Precautions âš ï¸**

- **Excretion**: After its therapeutic action, P-32 is excreted from the body mainly through the urine.
  
- **Protection**: Due to its radioactive nature, patients undergoing P-32 therapy are often advised to take specific precautions, especially around children and pregnant women, for a stipulated time post-therapy.

- **Side Effects**: The treatment is usually well-tolerated, but some patients may experience side effects due to the suppression of bone marrow activity, leading to reduced white blood cell, red blood cell, or platelet counts.


### ğŸ¦  **Radiosynovectomy (Radiopharmaceutical Synoviorthesis)**

Radiosynovectomy is a therapeutic procedure where radioactive agents are directly injected into the synovial cavity of a joint, mainly to alleviate symptoms of chronic synovitis (inflammation of the synovial membrane) which hasn't responded to standard medical treatments. 

#### **ğŸ¯ Aim & Mechanism of Action**

The primary goal is to:
1. Alleviate pain
2. Reduce swelling
3. Improve joint function

The radioactive particles emit beta radiation with a limited penetration range, which means their action is restricted to the joint's synovial membrane where they're injected. These particles induce localized inflammation leading to fibrosis and subsequent shrinkage of the inflamed synovium. By doing so, they can halt the disease progression, especially in joints where the synovium is actively producing excessive fluid or causing pain.

####**ğŸŒŸ Indications**

The common indications for radiosynovectomy include:
1. **Rheumatoid Arthritis (RA)**: For patients with persistent synovitis despite systemic treatments.
2. **Hemophilic Arthropathy**: Hemophiliacs often develop chronic synovitis due to repeated joint bleeds.
3. **Psoriatic Arthritis and other spondyloarthropathies**: Persistent joint inflammation despite treatment.
4. **Osteoarthritis with Synovitis**: In selected cases where inflammation is a significant contributor to symptoms.

#### **ğŸŒ¡ Radiopharmaceutical Agents & Their Usage**

The choice of radiopharmaceutical is based on the joint size:

1. **Yttrium-90 (Y-90) ğŸ§¬**: This is utilized for larger joints such as the knee. Due to its higher energy, it can penetrate the thick synovium present in larger joints effectively.

2. **Rhenium-186 (Re-186) ğŸ§ª**: Suitable for medium-sized joints, including the ankle or the wrist. It has a slightly lesser energy compared to Y-90, making it ideal for these joints.

3. **Erbium-169 (Er-169) ğŸ“Œ**: Used for smaller joints, typically those in the hands and feet. The low penetration depth ensures that the radiation affects only the synovium and not deeper structures.

#### **ğŸ” Procedure**

The procedure is relatively straightforward:

1. The joint is first aspirated to remove any excess synovial fluid.
2. The radiopharmaceutical agent is then injected into the joint cavity.
3. The joint is immobilized briefly post-procedure to prevent leakage of the agent.
4. Patients are usually advised certain precautions post-procedure to minimize radiation exposure to others.

#### **ğŸ‰ Benefits & Risks**

**Benefits**:
- Non-invasive compared to surgical synovectomy.
- Alleviates pain and reduces inflammation.
- Delays or even avoids the need for joint replacement surgery.

**Risks**:
- Temporary increase in joint pain post-procedure.
- Possibility of joint infection (though rare).
- Mild radiation exposure.

#### **ğŸ”— Contraindications**

Absolute contraindications include:
1. Joint infection
2. Skin infection at the injection site
3. Pregnancy


### **9ï¸âƒ£ Hemibody Irradiation (HBI) â˜¢ï¸**

Hemibody irradiation refers to the administration of therapeutic radiation to either the upper or lower half of the body. It is a form of palliative radiotherapy, primarily intended to alleviate symptoms, such as pain, rather than cure the disease. 

#### **Background and Principle ğŸ“š**

- The principle behind HBI is to deliver a uniform dose of radiation to widespread tumor sites within a large volume of the body, often when the disease has spread to bones.
- The most common indication for HBI has been the treatment of painful bony metastases in patients with widespread skeletal involvement, especially when other treatment modalities, such as localized radiation or systemic therapies, are either not effective or not feasible.
  
#### **Types of HBI ğŸŒ**

There are two primary forms:

1. **Upper HBI**: This targets the skeletal system from the top of the skull down to the L1 vertebra. It primarily includes the spine, ribs, and pelvis. It's often employed when there's extensive involvement of the spine and ribs.

2. **Lower HBI**: This targets from the L2 vertebra down to the tips of the toes. It encompasses the lower spine, pelvis, and long bones of the legs. It's useful when there's significant disease in the pelvis or lower extremities.

#### **Procedure and Technique ğŸ§ª**

- Before the procedure, bone scans or other imaging methods are used to ascertain the extent and distribution of skeletal metastases.
- The patient is positioned, and large radiation fields are used to cover the upper or lower body.
- Modern techniques employ linear accelerators, allowing for better dose distribution and sparing of critical organs.
- Treatment is usually given in a single fraction, although multiple treatments might be necessary for some patients.

#### **Benefits and Challenges ğŸŒŸâŒ**

**Benefits**:
- Provides rapid relief from pain associated with widespread bony metastases.
- It's a non-invasive treatment option for patients who are not candidates for surgery or localized radiation.

**Challenges**:
- Can cause side effects such as nausea, fatigue, and lowered blood counts.
- It's a palliative measure, meaning it is meant to relieve symptoms rather than cure the disease.
- Given its broad radiation field, it's critical to minimize exposure to healthy tissues and organs.

#### **Evolution and Current Status â³**

- While HBI was more common in the past, the advent of new systemic therapies, including bisphosphonates and radiopharmaceuticals like Radium-223, has reduced its use. 
- Advances in targeted radiation therapy techniques have also allowed for more localized treatment of multiple metastatic sites, offering an alternative to HBI.

In essence, while hemibody irradiation is a valuable tool in specific scenarios, evolving medical technologies and newer therapeutic agents have made it less common in today's clinical practice. However, for certain patients, it remains an effective option for symptom relief.


### ğŸ¦  **Radiolabeled Antibiotics in Nuclear Medicine**

#### **1ï¸âƒ£ Introduction**: 
Radiolabeled antibiotics take advantage of the selective uptake of antibiotics by bacteria, and when these antibiotics are labeled with a radionuclide, they can effectively target bacterial infections. This approach may be especially helpful in situations where infections are hard to treat due to antibiotic resistance or are difficult to localize.

#### **2ï¸âƒ£ Mechanism of Action ğŸ¯**:

- **Selective Targeting ğŸ§¬**: Antibiotics have a natural proclivity to target specific bacterial components or metabolic pathways. When these antibiotics are radiolabeled, they retain their targeting ability and also bring along the therapeutic (or diagnostic) abilities of the radionuclide.
  
- **Beta Emitters ğŸ’¥**: These emit high-energy electrons that can cause lethal damage to bacterial DNA and other vital structures. Their limited range ensures that only the targeted bacteria and their immediate surroundings are affected.

#### **3ï¸âƒ£ Applications ğŸ› **:

- **Chronic Infections ğŸ¦ **: Conditions like osteomyelitis, prosthetic joint infections, or chronic ulcers sometimes harbor bacteria that are deep-seated and challenging to treat. Radiolabeled antibiotics can deliver targeted radiation to these deep sites.

- **Drug-resistant Bacterial Infections ğŸ§«**: With the rise of superbugs or multidrug-resistant organisms, traditional antibiotics sometimes fall short. Radiolabeled antibiotics can offer an alternative therapeutic avenue, bringing radiation directly to the bacteria irrespective of their antibiotic resistance profile.

- **Infection Imaging ğŸ“¸**: Before the therapeutic application, some radiolabeled antibiotics can also be used diagnostically to pinpoint the exact location of an infection, especially in challenging cases where traditional imaging modalities are inconclusive.

#### **4ï¸âƒ£ Challenges and Concerns âš ï¸**:

- **Specificity ğŸ¯**: Ensuring that the radiolabeled antibiotic targets only the bacterial cells and not the host's cells is crucial. Unintended radiation to healthy tissues can cause adverse effects.

- **Penetration ğŸ’Š**: Some infections, like biofilm-associated infections, present challenges due to decreased penetration of antibiotics. The radiolabel might not reach all the bacteria in such cases.

- **Radiation Concerns â˜¢ï¸**: Like all therapies involving radiation, there's always a concern about the total radiation dose to the patient, especially if multiple treatments are needed.

#### **5ï¸âƒ£ Future Prospects ğŸŒŸ**:

With the increasing challenges posed by antibiotic-resistant bacteria, radiolabeled antibiotics are an exciting field of study. As research advances, we can expect more specific targeting, potentially with lower doses of radiation and increased efficacy against a broad spectrum of bacterial infections.



[Back to top](#nuclear-medicine-cheatsheet)



## Dosimetry & Safety

## **Dosimetry in Nuclear Medicine** 

### ğŸ“ **Basics of Dosimetry**:

**1ï¸âƒ£ Units of Measurement**:
- **Activity**: Measured in Becquerels (Bq) or Curies (Ci). It denotes the rate of decay or transformations per unit time.
  
- **Absorbed Dose**: Measured in Gray (Gy) or rad. It signifies the amount of energy deposited in a unit mass of tissue.
  
- **Equivalent Dose**: Measured in Sievert (Sv) or rem. It takes into account the type of radiation and its biological effectiveness.

### ğŸ§ª **Internal Dosimetry**:

This focuses on the dosimetry of radiopharmaceuticals that are ingested or injected into the body.

**1ï¸âƒ£ Biodistribution and Clearance**: Understanding how a radiopharmaceutical spreads throughout the body and how quickly it's excreted is essential. Various organs might uptake different amounts, leading to varied doses to each organ.

**2ï¸âƒ£ Time-Activity Curves**: These plots display the activity of a radionuclide within an organ or tissue over time, assisting in determining the dose delivered to that organ.

**3ï¸âƒ£ Dosimetry Software**: Advanced computational tools and software, like OLINDA/EXM, provide precise estimates of the dose based on biodistribution data.

### ğŸ–¥ï¸ **Patient-specific Dosimetry**:

As the field advances, there's an increasing emphasis on tailoring dose calculations to individual patients rather than relying on standard models. This includes:

- **3D Imaging**: Modern imaging modalities like SPECT and PET allow for 3D visualization, offering more detailed biodistribution data.
  
- **Phantom Models**: Physical or computational models that represent human anatomy. They can be adapted to match a specific patient's anatomy for accurate dose calculations.

### ğŸ” **Microdosimetry**:

This subfield focuses on the energy deposition in microscopic regions, reflecting the stochastic nature of radiation interactions. Especially crucial for alpha and beta emitters, where energy deposition events are localized.

### ğŸš€ **Future Prospects in Dosimetry**:

**1ï¸âƒ£ Advanced Computational Models**: The development of more sophisticated and realistic computational phantoms, including pediatric and pregnant models, for better dose assessments.

**2ï¸âƒ£ Personalized Treatment Planning**: Combining diagnostic imaging, dosimetry, and therapeutic applications to tailor treatments for individual patients, ensuring optimal therapeutic effects while minimizing risks.

**3ï¸âƒ£ AI and Machine Learning**: These technologies might play a role in automating and refining dose calculations, potentially improving the accuracy and efficiency of dosimetry in nuclear medicine.


### **3ï¸âƒ£ Radiation Biology: At the Cellular Level ğŸ§¬**

**A. Effects of Radiation**:
- **Direct Effect**: Ionizing radiation directly damages DNA.
  
- **Indirect Effect**: Radiation interacts with water molecules, producing reactive radicals that damage cellular components, including DNA.

- **Deterministic Effects**: Effects that have a threshold dose below which they will not occur. Above this dose, the severity of the effect increases with the dose.

- **Stochastic Effects**: No threshold dose. The probability of occurrence increases with dose, but the severity does not.

**B. Cellular Repair Mechanisms**:
- Cells have mechanisms to repair radiation-induced damage. However, repeated or high doses can overwhelm these systems, leading to cell death or malfunction.

### **4ï¸âƒ£ Current & Promising Future Aspects ğŸš€**

**A. 3D Dosimetry**:
- Advanced imaging techniques allow for 3D visualization of radiotracer distribution, enabling more accurate dosimetry calculations.

**B. Theranostics**:
- The combination of therapy and diagnostics. Using the same molecule for both imaging and treatment ensures that dosimetry calculations based on diagnostic imaging accurately reflect therapeutic scenarios.

**C. Real-time Dosimetry**:
- Emerging technologies aim to provide real-time feedback on the radiation dose being delivered, allowing for immediate adjustments if necessary.

**D. AI and Machine Learning in Dosimetry**:
- Leveraging AI for predicting radiation dose distribution, optimizing treatment protocols, and personalizing patient treatments.

## ğŸ§’ **Stochastic Effects of Radiation on Children**

### **1ï¸âƒ£ Understanding Stochastic Effects ğŸ²**

- **Definition**: Stochastic effects refer to radiation-induced health effects whose probability increases with dose but whose severity does not. Essentially, the more radiation one is exposed to, the higher the chance of an effect, but if the effect occurs, its intensity is not dose-dependent.
  
- **Random Nature**: These effects are random and can occur at any radiation level, but the probability is low at small doses.

### **2ï¸âƒ£ Why Children Are More Vulnerable ğŸ¼**

- **Cell Division Rate**: Children's cells divide rapidly as they grow, and radiation can cause DNA damage during division, potentially leading to mutations.

- **Longer Life Ahead**: Any radiation-induced mutation in a child's DNA has a longer time to manifest into a disease, such as cancer, than it would in an older individual.

- **Developing Organs**: Organs that are still developing are more sensitive to the harmful effects of radiation.

### **3ï¸âƒ£ Common Stochastic Effects in Children ğŸ©º**

**A. Leukemia**:
- Children exposed to significant amounts of radiation have an increased risk of developing leukemia, a type of blood cancer. 

**B. Solid Cancers**:
- Organs like the thyroid, breast, and brain are particularly sensitive in children, and radiation exposure can increase the risk of tumors in these organs.

**C. Hereditary Effects**:
- Though the evidence is limited, there is a concern about radiation-induced mutations being passed on to future generations.

### **4ï¸âƒ£ Mitigating Risks in Medical Settings ğŸ¥**

**A. ALARA Principle (As Low As Reasonably Achievable)**:
- Ensuring that the radiation dose is as low as possible, especially in diagnostic procedures like CT scans, while still achieving the necessary medical outcome.

**B. Tailored Protocols for Children**:
- Adjusting imaging protocols to minimize radiation dose while maintaining image quality.

**C. Frequent Reevaluation**:
- Reassessing the necessity of repeated imaging and considering alternative non-radiative imaging modalities when possible.

Given the vulnerability of children to radiation, it's crucial to handle their exposure with extreme care and caution. Medical professionals are trained to be especially careful when using radiation-based diagnostics or treatments on younger patients. Always consider the benefits and potential risks when exposing children to radiation.


### ğŸ§¬ **Stochastic Effects in Adults**

While children are more sensitive to radiation due to their rapidly dividing cells and longer life expectancy, adults also face risks from radiation exposure. The primary concern for adults regarding stochastic effects is the induction of cancer.

**1ï¸âƒ£ Cancer Induction**:
- **Mechanism**: Radiation can cause damage to the DNA within cells. Sometimes this damage gets repaired, but at other times, it may result in mutations. If these mutations occur in genes that control cell division, they can lead to uncontrolled growth and eventually cancer.
  
- **Types of Cancers**: Adults exposed to significant radiation doses have an increased risk of developing several types of cancers, including leukemia, breast cancer, lung cancer, and thyroid cancer, among others.

**2ï¸âƒ£ Radiation-induced Cataracts**:
- While traditionally viewed as a deterministic effect, recent data suggest that even lower doses than previously thought can increase the risk of cataract formation, making it a stochastic effect for adults.

**3ï¸âƒ£ Gender Differences**:
- **Women**: They have a somewhat higher risk than men of developing radiation-induced cancers after receiving the same exposures at the same ages. Breasts and thyroid are particularly sensitive.

- **Men**: While they have a slightly lower overall risk compared to women, they still face the possibility of radiation-induced cancers, especially of the lungs and stomach.

**4ï¸âƒ£ Factors Affecting Stochastic Risks in Adults**:
- **Age**: The risk diminishes with age, but it never disappears entirely. Older adults have less time for radiation-induced cancers to develop compared to younger adults.
  
- **Lifestyle Factors**: Smoking, alcohol consumption, and certain dietary habits can amplify the effects of radiation in inducing cancers.

- **Previous Radiation Exposure**: Cumulative radiation doses over time add up. Someone who has been exposed to significant radiation earlier in life has an increased risk if they are exposed again.

**5ï¸âƒ£ Genetic Predisposition**:
- Some individuals might be genetically predisposed to have higher sensitivity to radiation's effects. For them, even standard diagnostic doses can pose a higher risk of inducing stochastic effects.

### **In Summary**:
For adults, the primary stochastic risk from radiation is the induction of cancer. The amount of radiation exposure and individual factors like age, gender, lifestyle, and genetics play a role in determining this risk. It's always essential to weigh the benefits of a radiation-based medical procedure against its potential risks and ensure that the "As Low As Reasonably Achievable" (ALARA) principle is followed in clinical settings.


[Back to top](#nuclear-medicine-cheatsheet)

## Instrumentation & Quality Control
## **Instrumentation & Quality Control in Nuclear Medicine** ğŸ§ªğŸ”

### ğŸ›ï¸ **Instrumentation**:

**1ï¸âƒ£ Detectors**:

- **Geiger-MÃ¼ller Counters âš¡**: A common radiation detection instrument. It's sensitive but doesn't provide energy discrimination (can't differentiate between different types of radiation based on energy).

- **Scintillation Detectors âœ¨**: Use a crystal (like NaI(Tl)) that emits light (scintillates) when hit by radiation. Photomultiplier tubes then amplify this light to produce a measurable signal. Common in gamma cameras.

- **Semiconductor Detectors ğŸš**: Use semiconducting materials (like germanium or silicon) to detect radiation. They offer excellent energy resolution.

**2ï¸âƒ£ Imaging Systems**:

- **Gamma Cameras ğŸ“¸**: Widely used in nuclear medicine to image gamma rays. Comprises a collimator, scintillation detector, and electronic systems to process signals.

- **SPECT (Single Photon Emission Computed Tomography) ğŸŒ€**: Offers 3D imaging by rotating the gamma camera around the patient. Useful for functional imaging of organs.

- **PET (Positron Emission Tomography) ğŸ’¡**: Detects pairs of gamma rays emitted by a positron-emitting radionuclide. Offers high-resolution 3D images and is commonly used for oncology, cardiology, and neurology studies.

**3ï¸âƒ£ Advanced Systems**:

- **Hybrid Imaging Systems ğŸŒ**: Combines anatomical and functional imaging, such as SPECT/CT or PET/CT, to offer both structural and functional insights.

- **Time of Flight (TOF) PET ğŸ”¥**: Improves image quality by measuring the tiny time differences in gamma ray detection, thus increasing the signal-to-noise ratio.

### ğŸ“‹ **Quality Control (QC)**:

**1ï¸âƒ£ Purpose ğŸ¯**: 
Ensures that instruments are working optimally and provides accurate and consistent results. It safeguards patient safety by ensuring the minimum radiation dose is used for diagnosis or therapy.

**2ï¸âƒ£ Daily QC Tests ğŸ—“**:

- **Uniformity Tests â¬œ**: Ensure that the detector has uniform response across its field of view.
  
- **Center of Rotation Tests ğŸ”„**: For rotating systems like SPECT, ensuring that there's no spatial distortion during rotation.

**3ï¸âƒ£ Periodic QC Tests ğŸ“…**:

- **Spatial Resolution Tests ğŸ¯**: Assesses the system's ability to differentiate between two nearby points.
  
- **Energy Resolution Tests ğŸ“Š**: Checks the system's capability to distinguish different energy levels of incoming radiation.
  
- **High Count Rate Tests âš¡**: Assesses how the system performs under high radiation levels, ensuring linearity of response.

**4ï¸âƒ£ Advanced QC**:

- **Phantom Imaging ğŸ•º**: Using objects with known properties (phantoms) to evaluate imaging system performance. Phantoms can mimic specific organs or body parts.

- **Contrast and Noise Analysis ğŸŒ“**: Evaluates the system's ability to distinguish between regions of varying radioactivity and how noise affects this.

**5ï¸âƒ£ Documentation and Record-Keeping ğŸ“”**: 
Vital for compliance with regulations and to track instrument performance over time. Helps in early identification of potential issues and aids in preventive maintenance.

**6ï¸âƒ£ Continuous Training & Education ğŸ“**:
Ensuring that the personnel operating the instruments are well-trained and updated with the latest best practices and guidelines.

[Back to top](#nuclear-medicine-cheatsheet)


##  Recent Advances & Future Trends

### **1ï¸âƒ£ Radiomics & Artificial Intelligence (AI) ğŸ¤–**:
- **Radiomics**: The process of extracting a large number of features from radiographic images, which can be used for decision support in diagnostics and treatment planning.
  
- **AI and Machine Learning**: These technologies are being integrated with nuclear medicine to enhance image interpretation, automate processes, and predict patient outcomes.

### **2ï¸âƒ£ Theranostics ğŸ”â¡ï¸ğŸ’¡**:
- Combining diagnostics with therapeutics. Using the same radioactive molecule to both image and treat a disease, allowing for personalized medicine.
  
- Lutathera, for example, is used for both diagnosing and treating certain types of neuroendocrine tumors.

### **3ï¸âƒ£ New Radiotracers & Imaging Agents ğŸ§ª**:
- Ongoing research to develop novel radiotracers that target specific biochemical processes, providing more detailed and specific imaging information.

- For example, FES-PET for imaging estrogen receptors in breast cancer.

### **4ï¸âƒ£ Advances in Imaging Modalities ğŸ“¸**:
- **Digital PET**: Offering better spatial resolution and sensitivity compared to analog systems.
  
- **Total-body PET**: Provides faster scans with lower radiation doses.
  
- **Hybrid Imaging Enhancements**: Improved integration of modalities like PET/MRI, offering both functional and anatomical imaging concurrently.

### **5ï¸âƒ£ Targeted Radionuclide Therapy ğŸ¯**:
- Using alpha-emitting radionuclides (like Ra-223) for targeting and treating specific tumors. Alpha particles are high LET (linear energy transfer) radiation, causing significant damage to targeted cells.

### **6ï¸âƒ£ Nanomedicine and Drug Delivery ğŸššğŸ”¬**:
- Nanoparticles loaded with radionuclides for targeted imaging and therapy.
  
- Tailoring nanoparticles for better tissue penetration, retention, and specificity.

### **7ï¸âƒ£ Expansion in Non-Oncology Applications â¤ï¸ğŸ§ **:
- Advances in cardiac and neurology nuclear medicine imaging, like better tracers for early Alzheimer's detection or myocardial perfusion imaging.

### **8ï¸âƒ£ Radiation Dose Optimization ğŸ“‰â˜¢ï¸**:
- Techniques and technologies to minimize radiation exposure while maintaining image quality, ensuring patient safety.

### **9ï¸âƒ£ Molecular Imaging & Precision Medicine ğŸ”ğŸ§¬**:
- Imaging at the molecular and cellular level, allowing for early disease detection and treatment personalization based on individual patient profiles.

### **ğŸ”Ÿ Advances in Radiopharmacy ğŸŒ¡ï¸ğŸ”¬**:
- Developing more stable, effective, and safe radiopharmaceuticals.
  
- Automated synthesis modules for efficient radiotracer production.

### **ğŸ”ğŸ”œ Future Outlook**:
- With the increasing integration of AI, we can expect more personalized treatment plans and better predictive tools for patient outcomes.
  
- Continued research into new radiotracers will expand the range of diseases that can be diagnosed and treated using nuclear medicine.
  
- The growth of hybrid imaging modalities will offer comprehensive patient assessments, merging the best of different imaging worlds.
nt.

[Back to top](#nuclear-medicine-cheatsheet)

